Brain Tumour Conference 2024
We are pleased to announce the Cancer Research UK Brain Tumour Conference is returning for an in-person event in 2024.
We are delighted to welcome you back to London for three days of stimulating sessions designed to spark new opportunities for collaborative research. The Brain Tumour Conference 2024 will unite the brightest minds in cancer research to discuss and debate some of the greatest issues in the field.
Learning objectives
Although survival rates for most cancers have shown an encouraging upward trend, the fearsome complexity of the brain, and the plethora of different disease subtypes, has left brain tumour survival languishing at the bottom of the table.
Our intention is to provide a stimulating environment where scientists from across the research pipeline can showcase new discoveries, spark new collaborations, and create the synergy needed to accelerate progress for patients.
Our multidisciplinary programme combines expertise from across the breadth of brain tumour research, together with insights from allied disciplines, to provide attendees with the tools and techniques to apply to their own research.
There will be ample time throughout the conference to network with peers, view posters and continue thought-provoking conversations outside of the agenda.
Audience
This is a must-attend meeting for all disciplines interested in brain cancer, including established and early-career researchers, clinical experts in brain cancer and related fields.
COVID-19 guidance
The health and safety of our attendees and those you work with remain our highest priority. We will continue to closely monitor developments relating to COVID-19 and review guidance from government bodies. Further information and advice will be emailed to registered attendees ahead of the event.
Key information
Tuesday 24 – Thursday 26 September 2024
Park Plaza London Riverbank
This event will be CPD accredited
Early bird rate from £220 to £600
Standard rate from £320 to £700
Our sponsors
We're pleased to have Biomodal, Lunaphore, Cancer Research Horizons, Cancer Tools, Don Whitley Scientific Limited, Tessa Jowell Brain Cancer Mission, Stoelting Europe and Datar Cancer Genetics sponsoring this year's Brain Tumour Conference.
Biomodal is an omics-based life-sciences technology & analytics company. The groundbreaking multiomic solution, duet evoC reveals the power of the 6-base genome by distinguishing 5-methylcytosine & 5-hydroxymethylcytosine together with all 4 canonical bases to measure multiple modes of biology from a single 5ng DNA sample in a single experiment.
Lunaphore - a Bio-Techne brand, has the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology that can extract spatial proteomic and genomic data from tumours and transform any simple assay into multiplex spatial biology without complexity.
Cancer Research Horizons is the innovation arm of Cancer Research UK – the world's largest charitable funder of cancer research. To date, it has played an instrumental role in forming over 70 spin-out companies and bringing 11 cancer drugs to market, and enabling over 6 million courses of treatment for cancer patients across the world.
CancerTools.org is the first-of-its-kind non-profit, cancer-focused biorepository where researchers can deposit research tools they have developed in their labs, including antibodies, cell lines, organoids, small molecules, mouse models, cell culture media and other state-of-the-art technologies. We produce, store and supply these tools to fellow scientists in their research to deepen our understanding of cancer and drive innovation.
Don Whitley Scientific Limited specialises in the manufacture of oxygen-controlled workstations designed to help researchers study and condition their cell lines under in vivo oxygen conditions by serving as an incubator and hood in one. Whitley Workstations are used in key research fields such as tumour microenvironments, cell therapies, metabolism, inflammation, stem cell biology, and more.
The Tessa Jowell Brain Cancer Mission (TJBCM) is a convening body tasked by the UK Health Minister to deliver transformative national programmes to improve brain tumour research, treatments and care in the UK. The TJBCM runs a portfolio of eight innovative programmes focused on accelerating research, advancing clinical trial infrastructure, improving care for today’s patients and connecting and training NHS staff. Over 90 NHS doctors, nurses and scientists from across the UK work with the Mission to jointly design and deliver its programmes.
Stoelting Europe provides high-quality tools for pre-clinical neuroscience research, emphasizing the 3Rs ethical principles. They offer precise stereotaxic frames and accessories, user-friendly behavioral tracking software (ANY-maze), and exceptional customer support to ensure reliable, insightful research outcomes.
Datar Cancer Genetics delivers advanced cancer diagnostics using tissue and liquid biopsy for all stages. They hold a US-FDA Breakthrough Device designation for our TruBlood-CNS liquid biopsy test for brain tumour early detection. TruBlood-CNS research is published in the International Journal of Cancer with the Brain Tumour Research Centre, Imperial College London.
Sponsorship & Exhibition
If you are interested in sponsoring or exhibiting at the conference and have any questions, please contact:
Fiona Winwick
Research Events Manager
E: fiona.winwick@cancer.org.uk